These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 496148)

  • 21. [The effectiveness of the use of new types of antiparkinson agents].
    Federmann J; Honzáková L; Roth B; Stika L
    Cesk Zdrav; 1981 Jun; 29(6):229-41. PubMed ID: 7261170
    [No Abstract]   [Full Text] [Related]  

  • 22. Depression and dementia in Parkinson's disease. Catecholamine changes in the locus ceruleus, a basis for therapy.
    Chan-Palay V
    Adv Neurol; 1993; 60():438-46. PubMed ID: 8093581
    [No Abstract]   [Full Text] [Related]  

  • 23. Treatment with antiparkinson and antidepressant drugs: a register-based, pharmaco-epidemiological study.
    Brandt-Christensen M; Kvist K; Nilsson FM; Andersen PK; Kessing LV
    Mov Disord; 2007 Oct; 22(14):2037-42. PubMed ID: 17853463
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Protriptyline, a major tricycline antidepressant. Clinical and therapeutic study].
    Pluvinage R
    Therapie; 1969; 24(2):273-82. PubMed ID: 5769273
    [No Abstract]   [Full Text] [Related]  

  • 25. Antiparkinsonian drug administration and plasma levels of penfluridol, a new long-acting neuroleptic.
    Chouinard G; Annable L; Cooper S
    Commun Psychopharmacol; 1977; 1(4):325-31. PubMed ID: 615695
    [No Abstract]   [Full Text] [Related]  

  • 26. Parkinson's disease.
    Barboi AC; Goetz CG
    Clin Neuropharmacol; 1999; 22(4):184-91. PubMed ID: 10442246
    [No Abstract]   [Full Text] [Related]  

  • 27. Long-term effects of L-dopa and procyclidine on neuroleptic-induced extrapyramidal and schizophrenic symptoms.
    Chouinard G; Annable L; Mercier P; Turnier L
    Psychopharmacol Bull; 1987; 23(1):221-6. PubMed ID: 2885889
    [No Abstract]   [Full Text] [Related]  

  • 28. Dystonia not dystopia: effects of the legal high, 'Clockwork Orange'.
    Mackey HE; Hawksley O
    BMJ Case Rep; 2015 Dec; 2015():. PubMed ID: 26660763
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lack of indication for use of antiparkinson medication. A follow-up study.
    Pecknold JC; Ananth JV; Ban TA; Lehmann HE
    Dis Nerv Syst; 1971 Aug; 32(8):538-41. PubMed ID: 5094160
    [No Abstract]   [Full Text] [Related]  

  • 30. Studies on the action of certain pharmacological agents on tardive dyskinesia and on the rabbit syndrome.
    Jus K; Jus A; Gautier J; Villeneuve A; Pires P; Pineau R; Villeneuv R
    Int J Clin Pharmacol; 1974 Mar; 9(2):138-45. PubMed ID: 4827556
    [No Abstract]   [Full Text] [Related]  

  • 31. [Age profile of patients treated with psychopharmaceuticals].
    Kameníková L; Stika L; Plechatová H
    Cesk Farm; 1978 Jun; 27(4):182-7. PubMed ID: 699072
    [No Abstract]   [Full Text] [Related]  

  • 32. Intoxication with procyclidine (kemadrin), report of three cases.
    Caston JC; Randels PM; Keeler MA
    J S C Med Assoc; 1973 Feb; 69(2):37-9. PubMed ID: 4510091
    [No Abstract]   [Full Text] [Related]  

  • 33. Elamol and Motival-new psychotropic drugs?
    Drug Ther Bull; 1972 Oct; 10(21):83-4. PubMed ID: 4656671
    [No Abstract]   [Full Text] [Related]  

  • 34. [Improvements in motor and non-motor symptoms in parkinson patients under ropinirole therapy].
    Buchwald B; Angersbach D; Jost WH
    Fortschr Neurol Psychiatr; 2007 Apr; 75(4):236-41. PubMed ID: 17427044
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Incidents caused by psychotropic drugs in the aged. Personal cases].
    Bertolini R
    Minerva Psichiatr; 1979; 20(4):237-44. PubMed ID: 550040
    [No Abstract]   [Full Text] [Related]  

  • 36. Melanocyte-stimulating hormone and the hypothalamic hormone which inhibits its release.
    Kastin AJ; Barbeau A; Ehrensing RH; Plotnikoff NP; Schally AV
    Adv Neurol; 1974; 5():225-9. PubMed ID: 4216256
    [No Abstract]   [Full Text] [Related]  

  • 37. Use of antiparkinsonian drugs in the Umbria Region.
    Vanacore N; Bianchi C; Da Cas R; Rossi M
    Neurol Sci; 2003 Oct; 24(3):221-2. PubMed ID: 14600826
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of apomorphine in clinical practice.
    MacMahon DG
    Adv Neurol; 1999; 80():529-33. PubMed ID: 10410767
    [No Abstract]   [Full Text] [Related]  

  • 39. Low dosage of pergolide in the treatment of restless legs syndrome.
    Noël S; Korri H; Vanderheyden JE
    Acta Neurol Belg; 1998 Mar; 98(1):52-3. PubMed ID: 9606442
    [No Abstract]   [Full Text] [Related]  

  • 40. A pilot study of the clinical efficacy and safety of memantine for Huntington's disease.
    Ondo WG; Mejia NI; Hunter CB
    Parkinsonism Relat Disord; 2007 Oct; 13(7):453-4. PubMed ID: 17046312
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.